Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector

• Michael A. Thomas ,

  * E-mail: michael.thomas1@howard.edu (MAT); guroffm@mail.nih.gov (MRG)

  Current address: Department of Biology, Howard University, Washington, D. C., United States of America

  Affiliation Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Tinashe Nyanhete,

  Current address: Duke University, Durham, North Carolina, United States of America

  Affiliation Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Iskra Tuero,

  Affiliation Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• David Venzon,

  Affiliation Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Marjorie Robert-Guroff

  * E-mail: michael.thomas1@howard.edu (MAT); guroffm@mail.nih.gov (MRG)

  Affiliation Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯